# A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients

> **NCT00384137** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 128 (actual)

## Conditions studied

- Transplantation

## Interventions

- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00384137
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2014-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384137, "A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00384137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*